BRAF and astrocytoma (excluding glioblastoma): The few available PLGG patient derived cell lines, such as BT-40 with BRAF-V600E [28], a modified astrocytoma cell line [29] and Res189 with several malignant glioma mutations [30] would not serve as representative models for studying BRAF-fusion signaling and drug sensitivity.